Veterinary Medicines

Metrocare tablets 500 mg

Authorised
  • Metronidazole
Download as PDF

Product identification

Medicine name:
Metrocare tablets 500 mg
Metrocare vet - Tablett - 500 mg
Active substance:
  • Metronidazole
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Metronidazole
    500.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01XD01
  • QP51AA01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • 500 tablets - 50 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 50 tablets - 5 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 60 tablets - 6 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 40 tablets - 4 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 80 tablets - 8 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 70 tablets - 7 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 20 tablets - 2 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 100 tablets - 10 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 30 tablets - 3 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 250 tablets - 25 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 90 tablets - 9 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 10 tablets - 1 PVC-Aluminium-Oriented polyamide -Aluminium blister pack in a cardboard box.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 18-12154
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0239/002
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."